13 Facts About Bevacizumab

Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease.

Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor.

Bevacizumab was approved for medical use in the United States in 2004.

Bevacizumab was approved in the United States in February 2004, for use in metastatic colorectal cancer when used with standard chemotherapy treatment.

Bevacizumab has been examined as an add on to other chemotherapy drugs in people with non-metastatic colon cancer.

Related searches

Bevacizumab has been used by ophthalmologists in an off-label use as an intravitreal agent in the treatment of proliferative eye diseases, particularly for choroidal neovascular membrane in AMD.

Bevacizumab is the first available angiogenesis inhibitor in the United States.

Bevacizumab was originally derived from a mouse monoclonal antibody generated from mice immunized with the 165-residue form of recombinant human vascular endothelial growth factor.

Bevacizumab is a recombinant humanized monoclonal antibody and in 2004, it became the first clinically used angiogenesis inhibitor.

Bevacizumab's work validated the hypothesis of Judah Folkman, proposed in 1971, that stopping angiogenesis might be useful in controlling cancer growth.

Bevacizumab has been tested in ovarian cancer where it has shown improvement in progression-free survival but not in overall survival.

Bevacizumab has been investigated as a possible treatment of pancreatic cancer, as an addition to chemotherapy, but studies have shown no improvement in survival.

Bevacizumab has been studied as a treatment for cancers that grow from the nerve connecting the ear and the brain.